Marshall静脉乙醇输注联合导管消融治疗持续性房颤的VENUS随机临床试验
VENUS试验为美国12中心、单盲随机对照研究,纳入350例首次消融的持续性房颤患者,比较导管消融联合Marshall静脉乙醇输注与单纯导管消融的疗效。
要点
- 联合Marshall静脉乙醇输注可提高持续性房颤消融后6及12个月无复发率。
- 联合组房颤负荷为零比例78.3%,显著高于单纯消融组67.9%。
- 联合组二尖瓣周围阻滞成功率80.6%,显著优于单纯消融组51.3%。
核心结论
- 在持续性房颤患者中,导管消融联合Marshall静脉乙醇输注较单纯导管消融可提高6及12个月无房颤/房速复发可能性。
研究设计与样本
- VENUS为研究者发起、美国国立卫生研究院资助、12中心、单盲随机对照试验,2013年10月至2018年6月入组350例首次消融的持续性房颤患者。
- 患者按1:1.15随机分配至单纯导管消融组(n=158)或联合Marshall静脉乙醇输注组(n=185),以容纳15%技术失败率。
- 主要终点为单次手术后6及12个月均无>30秒房颤/房速且不使用抗心律失常药物,结局评估对随机分组设盲。
主要发现
- 12项次要结局中9项无显著差异,不良事件两组相似。
关键数值与推荐
- 主要终点:单次手术后6及12个月均无>30秒房颤/房速且不使用抗心律失常药物。
- 联合组Marshall静脉乙醇成功输注155/185例。
- 343例随机患者平均年龄66.5(SD 9.7)岁,男性261例,316例(92.1%)完成试验。
临床怎么用
- 对首次消融的持续性房颤患者,可考虑在导管消融基础上加用Marshall静脉乙醇输注以提高6至12个月无复发率。
- 该联合策略可能改善房颤负荷及二尖瓣周围阻滞成功率,但需权衡技术失败率。
局限性
- 随访仅至12个月,长期疗效需进一步研究评估。
- Marshall静脉乙醇输注存在技术失败,185例中仅155例成功输注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Catheter ablation of persistent atrial fibrillation (AF) has limited success. Procedural strategies beyond pulmonary vein isolation have failed to consistently improve results. The vein of Marshall contains innervation and AF triggers that can be ablated by retrograde ethanol infusion. OBJECTIVE: To determine whether vein of Marshall ethanol infusion could improve ablation results in persistent AF when added to catheter ablation. DESIGN, SETTING, AND PARTICIPANTS: The Vein of Marshall Ethanol for Untreated Persistent AF (VENUS) trial was an investigator-initiated, National Institutes of Health-funded, randomized, single-blinded trial conducted in 12 centers in the United States. Patients (N = 350) with persistent AF referred for first ablation were enrolled from October 2013 through June 2018. Follow-up concluded in June 2019. INTERVENTIONS: Patients were randomly assigned to catheter ablation alone (n = 158) or catheter ablation combined with vein of Marshall ethanol infusion (n = 185) in a 1:1.15 ratio to accommodate for 15% technical vein of Marshall ethanol infusion failures. MAIN OUTCOMES AND MEASURES: The primary outcome was freedom from AF or atrial tachycardia for longer than 30 seconds after a single procedure, without antiarrhythmic drugs, at both 6 and 12 months. Outcome assessment was blinded to randomization treatment. There were 12 secondary outcomes, including AF burden, freedom from AF after multiple procedures, perimitral block, and others. RESULTS: Of the 343 randomized patients (mean [SD] age, 66.5 [9.7] years; 261 men), 316 (92.1%) completed the trial. Vein of Marshall ethanol was successfully delivered in 155 of 185 patients. At 6 and 12 months, the proportion of patients with freedom from AF/atrial tachycardia after a single procedure was 49.2% (91/185) in the catheter ablation combined with vein of Marshall ethanol infusion group compared with 38% (60/158) in the catheter ablation alone group (difference, 11.2% [95% CI, 0.8%-21.7%]; P = .04). Of the 12 secondary outcomes, 9 were not significantly different, but AF burden (zero burden in 78.3% vs 67.9%; difference, 10.4% [95% CI, 2.9%-17.9%]; P = .01), freedom from AF after multiple procedures (65.2% vs 53.8%; difference, 11.4% [95% CI, 0.6%-22.2%]; P = .04), and success achieving perimitral block (80.6% vs 51.3%; difference, 29.3% [95% CI, 19.3%-39.3%]; P < .001) were significantly improved in vein of Marshall-treated patients. Adverse events were similar between groups. CONCLUSIONS AND RELEVANCE: Among patients with persistent AF, addition of vein of Marshall ethanol infusion to catheter ablation, compared with catheter ablation alone, increased the likelihood of remaining free of AF or atrial tachycardia at 6 and 12 months. Further research is needed to assess longer-term efficacy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01898221.
引用
- Valderrábano M, Peterson LE, Swarup V, et al. Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial. JAMA. 2020. PMID: 33107945. doi:10.1001/jama.2020.16195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。